Literature DB >> 22208644

Plasma thiol status is altered in children with mitochondrial diseases.

Heli Salmi1, James V Leonard, Shamima Rahman, Risto Lapatto.   

Abstract

OBJECTIVE: This study was undertaken to investigate thiol metabolism as a marker of oxidative stress and antioxidative defence capacity in a cohort of children with biochemically and/or genetically confirmed mitochondrial disease. Previous studies suggest that lower glutathione levels, which have been shown to further compromise mitochondrial function, may occur in these diseases. Better understanding of the pathogenesis of mitochondrial diseases is important in order to improve their treatment.
METHODS: We studied plasma and erythrocyte glutathione and cysteine levels, the activities of erythrocyte glutathione peroxidase (GPx), glutathione reductase (GR), glucose 6-phosphate dehydrogenase G6PDH) and glutathione S-transferase (GST), as well as the levels of erythrocyte thiobarbituric acid-reactive species (TBA-RS) and protein carbonyls in 10 children with a biochemical and/or genetic diagnosis of mitochondrial disease and six controls.
RESULTS: Levels of reduced cysteine (CYSH) as well as reduced to oxidised cysteine ratio were lower in plasma of patients with mitochondrial diseases (p = 0.008 and p = 0.02, respectively). Plasma levels of reduced glutathione (GSH) were low in patients with mitochondrial diseases, mostly below the detection limit. We did not detect significant differences in erythrocyte thiols or glutathione-related enzyme activities.
CONCLUSION: Plasma thiols and their redox state are altered in patients with mitochondrial diseases, suggesting an increase in oxidative stress and depletion of antioxidant supplies. If confirmed in further studies, this relative thiol deficiency could be an important factor in the pathophysiology of mitochondrial diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22208644     DOI: 10.3109/00365513.2011.646299

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  10 in total

Review 1.  The glutathione system: a new drug target in neuroimmune disorders.

Authors:  Gerwyn Morris; George Anderson; Olivia Dean; Michael Berk; Piotr Galecki; Marta Martin-Subero; Michael Maes
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

Review 2.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 3.  Reversible infantile mitochondrial diseases.

Authors:  Veronika Boczonadi; Boglarka Bansagi; Rita Horvath
Journal:  J Inherit Metab Dis       Date:  2014-11-19       Impact factor: 4.982

Review 4.  Emerging aspects of treatment in mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2015-05-12       Impact factor: 4.982

Review 5.  Development of pharmacological strategies for mitochondrial disorders.

Authors:  M Kanabus; S J Heales; S Rahman
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

6.  Quantifying small molecule phenotypic effects using mitochondrial morpho-functional fingerprinting and machine learning.

Authors:  Lionel Blanchet; Jan A M Smeitink; Sjenet E van Emst-de Vries; Caroline Vogels; Mina Pellegrini; An I Jonckheere; Richard J T Rodenburg; Lutgarde M C Buydens; Julien Beyrath; Peter H G M Willems; Werner J H Koopman
Journal:  Sci Rep       Date:  2015-01-26       Impact factor: 4.379

7.  The Effects of Ascorbate, N-Acetylcysteine, and Resveratrol on Fibroblasts from Patients with Mitochondrial Disorders.

Authors:  Liza Douiev; Devorah Soiferman; Corinne Alban; Ann Saada
Journal:  J Clin Med       Date:  2016-12-22       Impact factor: 4.241

Review 8.  Glutathione as a Redox Biomarker in Mitochondrial Disease-Implications for Therapy.

Authors:  Gregory M Enns; Tina M Cowan
Journal:  J Clin Med       Date:  2017-05-03       Impact factor: 4.241

9.  Altered 2-thiouridylation impairs mitochondrial translation in reversible infantile respiratory chain deficiency.

Authors:  Veronika Boczonadi; Paul M Smith; Angela Pyle; Aurora Gomez-Duran; Ulrike Schara; Mar Tulinius; Patrick F Chinnery; Rita Horvath
Journal:  Hum Mol Genet       Date:  2013-06-28       Impact factor: 6.150

10.  HIBCH mutations can cause Leigh-like disease with combined deficiency of multiple mitochondrial respiratory chain enzymes and pyruvate dehydrogenase.

Authors:  Sacha Ferdinandusse; Hans R Waterham; Simon J R Heales; Garry K Brown; Iain P Hargreaves; Jan-Willem Taanman; Roxana Gunny; Lara Abulhoul; Ronald J A Wanders; Peter T Clayton; James V Leonard; Shamima Rahman
Journal:  Orphanet J Rare Dis       Date:  2013-12-04       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.